These AMCP, AMCP Learn, and Journal of Managed Care + Specialty Pharmacy resources can help increase our understanding of health disparities, their impact, and the role of managed care pharmacy in mitigating them.
The aim of the AMCP Format is to identify comprehensive evidence and information elements that meet the evidentiary needs of HCDMs. The AMCP Format is designed to encourage sharing of objective, credible, and relevant information on medical products.
The role of digital therapeutics, software that delivers clinical benefits and prevents, manages, and treats medical conditions, has evolved in the past few years. Explore these resources from AMCP, AMCP Learn, and Journal of Managed Care & Specialty Pharmacy resources to learn more about these innovative therapies.
These AMCP, AMCP Learn, and Journal of Managed Care & Specialty Pharmacy resources will help advance the role of value-based contracts to improve access and affordability of medications.
The Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) was established to address anticipated needs for post-marketed evidence generation for novel biologics, their corresponding biosimilars and other related products.
November 2023 Legislative & Regulatory Briefing: AMCP’s Adam Colborn Gives a Legislative, Regulatory, and Judiciary Update on Trending Topics in the Pharmacy Space; AMCP Comments on Requirements Related to the Mental Health Parity and Addiction Act; Now Available: Key Takeaways from AMCP’s Aug. 2 IRA Workshop Kickoff; AMCP Comments on Discrimination on the Basis of Disability in HHS Programs or Activities; AMCP Celebrates America’s Managed Care Pharmacists During National Pharmacy Month; Register Now: Access, Affordability, and Outcomes: The Value of Managed Care Pharmacy Webinar.
On May 30, 2023, Food and Drug Administration (FDA) issued the proposed rule titled “Medication Guides: Patient Medication Information”. The purpose of this rule is to amend its human prescription drug product labeling regulations for Medication Guides (FDA approved written prescription drug product information distributed to patients). This action, if finalized, will require applicants to create a new type of Medication Guide, referred to as Patient Medication Information (PMI), for prescription drug products, including biological products, used, dispensed, or administered on an outpatient basis and for blood and blood components transfused in an outpatient setting. AMCP submitted comments in response to the proposed rule on November 27, 2023.